Stellar names Tessie Che to board
This article was originally published in Scrip
Stellar Biotechnologies, which develops keyhole limpet hemocyanin (KLH), an immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets, has named Dr Tessie Che to its board of directors. Dr Che is currently chair of the board of privately held Amaran Biotechnology, based in Taiwan. She also co-founded Optimer Pharmaceuticals in 1998, and served as chief operating officer and senior vice-president of corporate affairs at the company.
You may also be interested in...
Angeli Möller, recently spotlighted by In Vivo as a 2020 Rising Leader, has quickly moved up the ranks at Bayer and is now spearheading one of its key initiatives to bring artificial intelligence and machine learning technologies into the pharma business.
Coaching and mentoring are important tools for the leaders of today to be able to foster the next generation of talent in the biopharma sector. While the routes into industry have not changed dramatically – most leaders hold a master’s degree and/or PhD – the expectations of rising leaders have altered and the industry itself has become more collaborative.
In this first edition of In Vivo's ‘Rising Leaders’ list, the focus is on entrepreneurs and innovators who represent the next wave of creativity in health care.